199 related articles for article (PubMed ID: 20377404)
1. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
[TBL] [Abstract][Full Text] [Related]
2. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
3. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
MacLeod IJ; Rowley CF; Thior I; Wester C; Makhema J; Essex M; Lockman S
J Clin Virol; 2010 Jul; 48(3):162-7. PubMed ID: 20427228
[TBL] [Abstract][Full Text] [Related]
4. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
[TBL] [Abstract][Full Text] [Related]
5. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
[TBL] [Abstract][Full Text] [Related]
6. Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
Lehman DA; Wamalwa DC; McCoy CO; Matsen FA; Langat A; Chohan BH; Benki-Nugent S; Custers-Allen R; Bushman FD; John-Stewart GC; Overbaugh J
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):225-33. PubMed ID: 22395670
[TBL] [Abstract][Full Text] [Related]
7. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
Lalonde MS; Troyer RM; Syed AR; Bulime S; Demers K; Bajunirwe F; Arts EJ
J Clin Microbiol; 2007 Aug; 45(8):2604-15. PubMed ID: 17567789
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Lallemant M; Ngo-Giang-Huong N; Jourdain G; Traisaithit P; Cressey TR; Collins IJ; Jarupanich T; Sukhumanant T; Achalapong J; Sabsanong P; Chotivanich N; Winiyakul N; Ariyadej S; Kanjanasing A; Ratanakosol J; Hemvuttiphan J; Kengsakul K; Wannapira W; Sittipiyasakul V; Pornkitprasarn W; Liampongsabuddhi P; McIntosh K; Van Dyke RB; Frenkel LM; Koetsawang S; Le Coeur S; Kanchana S;
Clin Infect Dis; 2010 Mar; 50(6):898-908. PubMed ID: 20158398
[TBL] [Abstract][Full Text] [Related]
9. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
10. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF; Bao Y; Lockman S; Halvas EK; Kearney MF; McIntyre JA; Schooley RT; Hughes MD; Coffin JM; Mellors JW;
J Infect Dis; 2014 Mar; 209(5):703-10. PubMed ID: 24443547
[TBL] [Abstract][Full Text] [Related]
11. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
Milne RS; Silverman RA; Beck IA; Mckernan-Mullin J; Deng W; Sibley TR; Dross S; Kiarie JN; Sakr SR; Coombs RW; Chung MH; Frenkel LM
AIDS; 2019 May; 33(6):941-951. PubMed ID: 30946148
[TBL] [Abstract][Full Text] [Related]
12. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S; Boltz V; Martinson N; Maldarelli F; Gray G; McIntyre J; Mellors J; Morris L; Coffin J
Proc Natl Acad Sci U S A; 2006 May; 103(18):7094-9. PubMed ID: 16641095
[TBL] [Abstract][Full Text] [Related]
13. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
[TBL] [Abstract][Full Text] [Related]
14. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
15. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
[TBL] [Abstract][Full Text] [Related]
16. Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Micek MA; Blanco AJ; Carlsson J; Beck IA; Dross S; Matunha L; Seidel K; Montoya P; Gantt S; Matediana E; Jamisse L; Gloyd S; Frenkel LM
J Infect Dis; 2012 Jun; 205(12):1811-5. PubMed ID: 22492850
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
18. Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.
Omondi EO; Muigai A; Ngayo MO; Mungiria J; Lihana R
Medicine (Baltimore); 2022 Dec; 101(50):e32346. PubMed ID: 36550885
[TBL] [Abstract][Full Text] [Related]
19. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Jourdain G; Ngo-Giang-Huong N; Le Coeur S; Bowonwatanuwong C; Kantipong P; Leechanachai P; Ariyadej S; Leenasirimakul P; Hammer S; Lallemant M;
N Engl J Med; 2004 Jul; 351(3):229-40. PubMed ID: 15247339
[TBL] [Abstract][Full Text] [Related]
20. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
